IN8bio stops glioblastoma trial, cuts workforce to focus on leukemia therapy

IN8bio has recently decided to halt its phase 2 clinical trial for newly diagnosed glioblastoma and lay off half of its workforce. The company has put the development of its INB-400 autologous gamma-delta T-cell therapy on hold and suspended patient enrollment while seeking partnership opportunities for the program. This decision will reduce the biotech's workforce from 37 to 19 full-time employees, impacting teams located in New York City and Birmingham, Alabama, according to a filing with the Securities and Exchange Commission. Additionally, the executive team will experience an 11% salary reduction starting September 1.

Originally known as Incysus Therapeutics, IN8bio is now focusing its efforts on INB-100, an allogeneic cell therapy intended for patients with acute myeloid leukemia (AML) undergoing bone marrow transplants. According to a September 4 announcement, the company received guidance from the FDA earlier this summer to further advance the INB-100 program. As part of this development, a control cohort will be added to the ongoing phase 1 trial. The funds generated from this strategic shift will be used to support the expanded trial cohort, which aims to enroll approximately 25 patients.

As of August 30, the company reported that none of the patients who have received INB-100 have experienced a relapse of their disease. IN8bio also plans to continue the phase 1 trial for another cell therapy, INB-200, aimed at treating newly diagnosed glioblastomas.

CEO and co-founder William Ho expressed confidence in the company's clinical programs, stating, "The data across both of our INB-100 and INB-200 clinical programs remain positive and robust. We are committed to building upon the data for INB-100 in AML, and we are making the difficult decision to advance fewer pipeline programs, reduce our spend and focus on key milestones that can help to generate near-term interest and value creation."

IN8bio, which is based in Birmingham, went public in 2022 but raised just over $10 million in its initial public offering, falling short of its $69 million goal. By the end of June, the company had $10.2 million in its bank accounts, a significant decrease from the $21.3 million it had at the beginning of 2024.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!